

TABLE OF CONTENTS

	Page
DECLARATION	ii
DEDICATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENTS	v
TABLE OF CONTENTS	vi
LIST OF FIGURES	viii
LIST OF TABLES	ix
LIST OF ABBREVIATIONS	x
1.0 INTRODUCTION	1
1.1 Warfarin embryopathy	1
1.2 Literature review	4
1.3 Study objectives and aims	13
1.4 Limitations of the study	14
1.5 Uniqueness of the study	15
2.0 SUBJECTS AND METHODS	16
2.1 Patient ascertainment	16
2.2 Interview schedule	17
2.3 Statistical analysis	19

3.0 RESULTS	20
3.1 Demographic data	20
3.2 Medication	20
3.3 Patient awareness	21
3.4 Pregnancy outcomes	23
3.5 Management practices	27
4.0 DISCUSSION	32
4.1 Patient awareness	32
4.2 Pregnancy outcomes	34
4.3 Management practices	36
5.0 CONCLUSION	45
5.1 Patient awareness	45
5.2 Pregnancy outcomes	46
5.3 Management practices	48
5.4 Future considerations	50
APPENDIX A Patient interview schedule	52
REFERENCES	55

LIST OF FIGURES

Figure	Page
3.1 Pregnancy outcomes comparing women on and off warfarin	24
3.2 Expected versus reported trends for timing of warfarin exposure for pregnancies one and two	29

LIST OF TABLES

Table	Page
3.1 Outcomes for warfarin-exposed and warfarin non-exposed pregnancies	24
3.2 Outcomes for first and second warfarin–exposed pregnancies	26
3.3 Outcomes for first and second pregnancies not exposed to warfarin	27
3.4 Reported timing of warfarin exposure for pregnancies one and two	28
3.5 Attendance at the Antenatal Obstetric Cardiac Clinic	30
3.6 INR values for patients on the day of the interview, at the previous visit, and six months prior to the interview	31

LIST OF ABBREVIATIONS

ACE – angiotensin converting enzyme

ARSE – arylsulfatase E

CHB – Chris Hani-Baragwanath

CNS – central nervous system

CPDX – X-linked recessive chondrodysplasia punctata

INR – international normalized ratio

OCC – Obstetric Cardiac Clinic

POC – point-of-care

TEC – thromboembolic complications

TOP – termination of pregnancy

SA – South Africa

WE – warfarin embryopathy